Genix Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul '25 Jul 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020
Net Income	-0.09	-0.07	-4.4	-1.07	-1.65	-0.72
Depreciation & Amortization	-0	-	0.55	0.56	0.54	0.36
Other Amortization	0	0	0	0	0	0
Asset Writedown & Restructuring Costs	-	-	3.46	-	-	-
Stock-Based Compensation	0.03	0.03	0.06	0.26	0.81	0.1
Other Operating Activities	-0.13	-0.17	0.06	0.04	0	-
Change in Accounts Receivable	0	-0	0.02	-0.01	0	-0
Change in Inventory	-0	-0	0.01	-0.17	-0	-
Change in Accounts Payable	0.04	0.04	0.03	0.18	-0.09	0.08
Change in Other Net Operating Assets	0.01	-0	-0	-0	-0.03	-0.01
Operating Cash Flow	-0.13	-0.19	-0.22	-0.22	-0.43	-0.2
Sale (Purchase) of Intangibles	-	-	-	-0	-	-0.01
Investing Cash Flow	-	-	-	-0	-	-0.01
Short-Term Debt Issued	-	0.19	0.28	0.17	-	-
Total Debt Issued	0.13	0.19	0.28	0.17	-	-
Short-Term Debt Repaid	-	-	-	-	-	-0.01
Long-Term Debt Repaid	-	-	-	-0.02	-0.01	-
Total Debt Repaid	-	-	-	-0.02	-0.01	-0.01
Net Debt Issued (Repaid)	0.13	0.19	0.28	0.15	-0.01	-0.01
Issuance of Common Stock	-	-	-	-	-	1.01
Other Financing Activities	-	-	-0.06	-0.05	-0.12	-0.13
Financing Cash Flow	0.13	0.19	0.22	0.09	-0.13	0.87
Net Cash Flow	-0.01	-0	0	-0.13	-0.56	0.67
Free Cash Flow	-0.13	-0.19	-0.22	-0.22	-0.43	-0.2
Free Cash Flow Margin	-196135.29%	-4624.54%	-1787.27%	-	-	-
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.01	-0.00
Cash Interest Paid	-	-	-	0	-	-
Levered Free Cash Flow	-0.51	-0.53	0.06	0.17	0.68	0.29
Unlevered Free Cash Flow	-0.41	-0.46	0.09	0.18	0.68	0.29
Change in Working Capital	0.06	0.03	0.06	-0.01	-0.12	0.07

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.